HK1129127A1 - Mcp-1 binding nucleic acids - Google Patents
Mcp-1 binding nucleic acidsInfo
- Publication number
- HK1129127A1 HK1129127A1 HK09107304.7A HK09107304A HK1129127A1 HK 1129127 A1 HK1129127 A1 HK 1129127A1 HK 09107304 A HK09107304 A HK 09107304A HK 1129127 A1 HK1129127 A1 HK 1129127A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nucleic acids
- mcp
- binding nucleic
- type
- nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06002935 | 2006-02-14 | ||
EP06024202 | 2006-11-22 | ||
PCT/EP2007/001294 WO2007093409A2 (en) | 2006-02-14 | 2007-02-14 | Mcp-i binding nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1129127A1 true HK1129127A1 (en) | 2009-11-20 |
Family
ID=38198593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107304.7A HK1129127A1 (en) | 2006-02-14 | 2009-08-10 | Mcp-1 binding nucleic acids |
Country Status (17)
Country | Link |
---|---|
US (4) | US8193159B2 (es) |
EP (3) | EP2135949B1 (es) |
JP (1) | JP5537812B2 (es) |
KR (2) | KR101572893B1 (es) |
CN (2) | CN101415825B (es) |
AT (1) | ATE510014T1 (es) |
AU (1) | AU2007214668B2 (es) |
BR (1) | BRPI0707842B8 (es) |
CA (1) | CA2638847C (es) |
DK (1) | DK2135949T3 (es) |
ES (1) | ES2397803T3 (es) |
HK (1) | HK1129127A1 (es) |
MX (2) | MX337801B (es) |
PL (1) | PL2135949T3 (es) |
PT (1) | PT2135949E (es) |
RU (1) | RU2518330C2 (es) |
WO (1) | WO2007093409A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2135949B1 (en) | 2006-02-14 | 2012-10-17 | Noxxon Pharma AG | MCP-1 binding nucleic acids |
US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
CN101878305A (zh) * | 2007-11-30 | 2010-11-03 | 诺松制药股份公司 | 结合mcp-1的核酸及其用途 |
JP5559159B2 (ja) * | 2008-06-11 | 2014-07-23 | バイオニュークレオン ソチエタ・レスポンサビリタ・リミタータ | 修飾オリゴヌクレオチドを使用するhrp−3の阻害 |
WO2010070394A1 (en) * | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
WO2012025251A1 (en) * | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
AU2013289880B2 (en) | 2012-07-13 | 2018-08-02 | Wave Life Sciences Ltd. | Chiral control |
JP2017502075A (ja) | 2013-11-04 | 2017-01-19 | ノクソン ファーマ エージー | 腎障害治療の手段および方法 |
WO2021178923A1 (en) | 2020-03-06 | 2021-09-10 | Drinksavvy, Inc. | Devices and methods for detecting a target analyte of interest |
WO2023154452A1 (en) | 2022-02-11 | 2023-08-17 | Waypoint Bio, Inc. | Cellular staining probes for analyte detection |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
DE50214456D1 (de) | 2001-10-26 | 2010-07-08 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
EP1386972A1 (en) * | 2002-08-01 | 2004-02-04 | Noxxon Pharma AG | Method and apparatus for designing a nucleic acid having a desired property |
EP1530635B1 (en) | 2002-08-01 | 2011-06-15 | Noxxon Pharma AG | Ghrelin binding nucleic acids |
KR101189555B1 (ko) | 2004-02-09 | 2012-10-16 | 주프라몰 파렌테랄 콜로이츠 게엠베하 | 폴리사카라이드 및 폴리뉴클레오티드로부터 접합체를제조하는 방법 |
US20060030535A1 (en) | 2004-03-05 | 2006-02-09 | Healy Judith M | Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics |
US20080299130A1 (en) | 2004-05-04 | 2008-12-04 | University Of Kentucky Research Foundation | Methods And Compositions For The Treatment Of Ocular Neovascularization |
EP2135949B1 (en) | 2006-02-14 | 2012-10-17 | Noxxon Pharma AG | MCP-1 binding nucleic acids |
US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
SG10201600632QA (en) * | 2007-08-06 | 2016-03-30 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof |
CN101878305A (zh) | 2007-11-30 | 2010-11-03 | 诺松制药股份公司 | 结合mcp-1的核酸及其用途 |
-
2007
- 2007-02-14 EP EP09012826A patent/EP2135949B1/en active Active
- 2007-02-14 WO PCT/EP2007/001294 patent/WO2007093409A2/en active Application Filing
- 2007-02-14 JP JP2008554674A patent/JP5537812B2/ja active Active
- 2007-02-14 AT AT07722818T patent/ATE510014T1/de not_active IP Right Cessation
- 2007-02-14 PT PT90128265T patent/PT2135949E/pt unknown
- 2007-02-14 ES ES09012826T patent/ES2397803T3/es active Active
- 2007-02-14 DK DK09012826.5T patent/DK2135949T3/da active
- 2007-02-14 RU RU2008136907/10A patent/RU2518330C2/ru active IP Right Revival
- 2007-02-14 KR KR1020137020808A patent/KR101572893B1/ko not_active IP Right Cessation
- 2007-02-14 MX MX2011010706A patent/MX337801B/es unknown
- 2007-02-14 EP EP11001720.9A patent/EP2365080B1/en not_active Not-in-force
- 2007-02-14 MX MX2016003546A patent/MX351107B/es unknown
- 2007-02-14 PL PL09012826T patent/PL2135949T3/pl unknown
- 2007-02-14 CA CA2638847A patent/CA2638847C/en active Active
- 2007-02-14 AU AU2007214668A patent/AU2007214668B2/en active Active
- 2007-02-14 CN CN2007800113050A patent/CN101415825B/zh active Active
- 2007-02-14 US US12/279,183 patent/US8193159B2/en active Active
- 2007-02-14 CN CN2013101587615A patent/CN103275984A/zh active Pending
- 2007-02-14 BR BRPI0707842A patent/BRPI0707842B8/pt active IP Right Grant
- 2007-02-14 KR KR1020087022289A patent/KR101475865B1/ko active IP Right Grant
- 2007-02-14 EP EP07722818A patent/EP1984501B1/en not_active Not-in-force
-
2009
- 2009-08-10 HK HK09107304.7A patent/HK1129127A1/xx unknown
-
2012
- 2012-06-04 US US13/487,341 patent/US8691784B2/en active Active
-
2014
- 2014-04-06 US US14/246,134 patent/US9670491B2/en active Active
-
2017
- 2017-06-06 US US15/614,665 patent/US10273480B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1129127A1 (en) | Mcp-1 binding nucleic acids | |
MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
MX2010003109A (es) | Acidos nucleicos de enlace c5a. | |
WO2008146745A1 (ja) | 新規なリゾホスファチジン酸アシル基転移酵素遺伝子 | |
WO2007062160A3 (en) | Methods and compositions for sequencing a nucleic acid | |
WO2009139630A9 (en) | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means | |
ATE541944T1 (de) | Polynukleotidprimer | |
NZ607870A (en) | Lactococcus crispr-cas sequences | |
EP2647711A3 (en) | Alternative export pathways for vector expressed RNA interference | |
MX2010001856A (es) | Proteina. | |
WO2008109142A3 (en) | Pirna and uses related thereto | |
EP3037401A3 (en) | 14-hydroxy-docosahexaenoic acid compounds | |
WO2008009477A3 (en) | Means for inhibiting the expression of protein kinase 3 | |
WO2009047992A1 (ja) | Udp-グルクロン酸転移酵素およびそれをコードするポリヌクレオチド | |
WO2008016906A3 (en) | 3'-phosphate-labeled nucleotide analogs and their use for sequencing a nucleic acid | |
WO2010057242A3 (de) | Vakzin | |
ATE536360T1 (de) | Neues nukleinsäuretransfersystem | |
EP2046394A4 (en) | USE OF NUCLEIC ACID SEQUENCES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES, VECTORS AND COMPOSITIONS | |
WO2009111440A3 (en) | Methods and compositions for reducing nucleotide impurities | |
DE50213015D1 (de) | Lipase-varianten | |
MX2008013416A (es) | Medios para inhibir la expresion de cd31. | |
WO2009054511A1 (ja) | 新規なatp:クエン酸リアーゼ遺伝子 | |
WO2009008466A1 (ja) | ホスファチジン酸ホスファターゼホモログとその利用 | |
WO2007144492A3 (fr) | Peptides a activite anti-proliferative | |
EP1752537A4 (en) | 9-FATTY ACID HYDROPEROXIDE LYASE GENES |